Supernus Pharmaceuticals (SUPN) awards 2,500 performance share units

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. reported that Sr. VP of IP, CSO Padmanabh P. Bhatt acquired 2,500 Performance Share Units on July 29, 2026. These units, each tied to one share of Common Stock and granted at $0.00, relate to an award made on February 19, 2025 that vested upon achieving individual performance objectives established on May 3, 2025. Following this award, Bhatt holds 2,500 Performance Share Units directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bhatt Padmanabh P.

Role Sr. VP of IP, CSO

Type	Security	Shares	Price	Value
Grant/Award	Performance Share Unit F1	2,500	$0.00	$0.00

Holdings After Transaction: Performance Share Unit — 2,500 shares (Direct)

Footnotes (1)

1. F1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Key Figures

Performance share units acquired: 2,500.0000 units Transaction price per unit: $0.0000 Underlying common shares: 2,500.0000 shares +3 more

6 metrics

Performance share units acquired 2,500.0000 units Derivative award reported for July 29, 2026

Transaction price per unit $0.0000 Grant of Performance Share Units as equity compensation

Underlying common shares 2,500.0000 shares Common Stock underlying the Performance Share Units

Total Performance Share Units after transaction 2,500.0000 units Direct derivative holdings following the reported acquisition

Award date February 19, 2025 Date the Performance Share Units were originally awarded

Performance objectives established May 3, 2025 Date individual performance objectives for the award were set

Key Terms

Performance Share Units, Common Stock, Sr. VP of IP, CSO

3 terms

Performance Share Units financial

"the Reporting Person was awarded Performance Share Units, a portion of which vested"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Sr. VP of IP, CSO other

"officer_title: Sr. VP of IP, CSO"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/31/2026 - 05:05 PM Accepted by SEC EDGAR 07/31/2026 - 05:04 PM Learn about SEC filing dates

FAQ

What insider transaction did Supernus Pharmaceuticals (SUPN) report for Padmanabh P. Bhatt?

Supernus Pharmaceuticals reported that Padmanabh P. Bhatt, Sr. VP of IP and CSO, acquired 2,500 Performance Share Units on July 29, 2026. Each unit represents underlying Common Stock and was granted at $0.00 as part of his equity compensation.

How many performance share units did the Supernus (SUPN) executive acquire in this Form 4?

The executive acquired 2,500 Performance Share Units. These derivative awards correspond to 2,500 shares of Common Stock and were granted at no cost, increasing his directly held Performance Share Units to a reported total of 2,500 units after the transaction.

What is the origin of the performance share units reported in this Supernus (SUPN) filing?

The units stem from an award granted on February 19, 2025. According to the disclosure, a portion of those Performance Share Units vested upon achieving individual performance objectives within a defined performance period, with those objectives established on May 3, 2025.

What is the transaction price for the Supernus (SUPN) performance share units granted to Bhatt?

The Performance Share Units were granted at a transaction price of $0.00 per unit. This indicates the award represents stock-based compensation rather than a market purchase, with value tied to the underlying Common Stock performance over time.

Does this Supernus (SUPN) insider transaction involve a Rule 10b5-1 trading plan?

The disclosure indicates the Rule 10b5-1 checkbox is not marked as affirmative. The reported activity is a grant or vesting of Performance Share Units, not an open-market trade executed under a pre-arranged trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhatt Padmanabh P.

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP of IP, CSO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	$0	07/29/2026		A		2,500		(1)	(1)	Common Stock	2,500	$0	2,500	D

Explanation of Responses:

1. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)